In response to TIME, “Compounding Pharmacies For Weight-Loss Drugs Are Booming. Should You Trust Them?” (October 7, 2026):
Online sellers and telehealth platforms are making it easier than ever to access unapproved GLP-1 drugs, often after little more than a brief questionnaire. Even when a doctor determines a medication is not appropriate for a patient, these channels may offer a pathway to obtaining it anyway. As TIME’s reporting makes clear, the booming market for compounded GLP-1s is raising serious questions about who is protecting patients – and who is profiting from gaps in oversight.
The concern is not legitimate compounding that serves a very narrow, patient-specific purpose. It is the large-scale production and misleading marketing of unapproved medicines that circumvent established safeguards and put patients at risk.
TIME’s reporting underscores why these distinctions matter. The Food and Drug Administration continues to warn that unapproved GLP-1 products are not reviewed for safety, effectiveness, or quality, and that compounded products should only be used when an FDA-approved treatment cannot meet a patient’s medical needs. Yet patients are being drawn to compounded alternatives without necessarily understanding the risks or differences.
The rules are in place for a reason. What is needed now is consistent enforcement, greater accountability for those operating outside the law, and a commitment to protecting patients before harm occurs – not after.
Fred H. Mills, Jr. is a compounding pharmacist with more than 50 years of experience, a former Louisiana State Senator, and former Executive Director of the Louisiana State Board of Pharmacy. He is Chief Policy Officer of Americans for Safe and Effective Medicines (ASEM).